Concordance among Gene-Expression–Based Predictors for Breast Cancer

Fan, Cheng; Oh, Daniel S.; Wessels, Lodewyk F.A.; Weigelt, Britta; Nuyten, Dimitry S.A.; Nobel, Andrew B.; Veer, Laura J. van’t; Perou, Charles M.

doi:10.1056/nejmoa052933

Cited by 1,184 publications

(913 citation statements)

References 16 publications

Supporting

Mentioning

862

Contrasting

Unclassified

Order By: Relevance

“…In contrast to a previous study comparing prognostic gene profiles where high concordance among classifiers was observed [24], profiles predicting outcome after tamoxifen treatment did not show high agreement in their classification. They classified only 45-61% of patients in the same category.…”

Section: Discussioncontrasting

confidence: 99%

See 1 more Smart Citation

Comparison of gene expression profiles predicting progression in breast cancer patients treated with tamoxifen

Kok

Linn

Laar

et al. 2008

Breast Cancer Res Treat

View full text Add to dashboard Cite

Section: Discussioncontrasting

confidence: 99%

“…Although this may result in an underestimation of the capacity of the 21-gene set, previous work suggests that applying the 21 genes to a microarray dataset results in accurate prediction of subgroups of patients [24,25].…”

Section: Discussionmentioning

confidence: 99%

Comparison of gene expression profiles predicting progression in breast cancer patients treated with tamoxifen

Kok

Linn

Laar

et al. 2008

Breast Cancer Res Treat

View full text Add to dashboard Cite

“…The breast cancer specific survival in these patients correlated with hormone receptor status of the tumors for both HER-2-negative and HER-2-positive tumors. This has been confirmed in various ethnic populations [25][26][27][28][29][30]. Therefore, they can be used to estimate the prevalence of the five intrinsic subtypes in epidemiological studies without loss of their prognostic significance [22,25,31].…”

Section: Introductionmentioning

confidence: 70%

Short-term outcome of primary operated early breast cancer by hormone and HER-2 receptors

Brouckaert

Pintens

Belle

et al. 2008

Breast Cancer Res Treat

View full text Add to dashboard Cite

Introduction Prognostic subgroup classification of operable breast cancers using cDNA clustering of breast cancer-related genes resembles the classification based on the combined immunohistochemical (IHC) expression of the hormone and HER-2 receptors. We here report the shortterm disease-free interval (DFI) of operable breast cancers by their joint hormone receptor/HER-2 phenotype. Patients and methods Short-term follow-up (FU) of a prospective cohort of 1,958 breast-cancer patients primary operated at our institution between 2000 and 2005. Receptors were evaluated using IHC. Steroid receptors were considered positive for any nuclear staining; HER-2 for strong (3+) membrane staining or positive fluorescence in situ hybridization (FISH). Kaplan-Meier (KM) DFI curves were calculated for any relapse defined as a local, regional, contralateral, or distant breast cancer event for the six predefined breast cancer subgroups: ER + PR + HER-2 -(PPN), ER + PR -HER-2 -(PNN), ER + PR + HER-2 + (PPP), ER -PR -HER-2 -(NNN), ER -PR -HER-2 + (NNP), and ER + PR -HER-2 + (PNP). P-values were calculated for comparison of the six different survival curves using two possible adaptations for multiple testing. A multivariate model for the receptors predicting DFI did incorporate local and systemic adjuvant therapy. Results Median patient age was 57 years (ranges 26-96) and median FU was 3.35 years. Overall, DFI at median FU was 91%; 94% for PPN, 89% for PNN, 86% for NNN, 81% for PPP, 80% for PNP, and 76% for NNP cases. Some receptor subgroups had a significantly better DFI than others based on multiple testing, especially when the PPN group was compared against the four most frequent subtypes. The multivariate model with local and systemic adjuvant therapy confirmed the prognostic value of ER, PR, and HER-2 for short-term DFI. Conclusion It is possible to distinguish short-term prognostic breast cancer subgroups only on the basis of ER, PR, and HER-2 even when stratified for local and systemic adjuvant therapy. While gene expression profiles based on microarray data of over hundreds of genes will probably teach us much about breast cancer biology, heterogeneity, and prognosis, we emphasize the important short-term prognostic value of currently used IHC markers for ER, PR, and HER-2.

show abstract

“…17,114,115 In fact, some studies have demonstrated that expression of basal keratins is a prognostic factor independent of tumor size, grade, and lymph node status. 114 However, when compared with either ERÀ non-basal-like cancers 72 or grade-matched non-basal-like cancers, 42 carcinomas with a basal-like phenotype are not associated with a poorer outcome in some studies, whereas a more adverse prognosis is observed in others.…”

Section: Clinical Behavior Of Basal-like and Triple-negative Breast Cmentioning

confidence: 99%

Basal-like and triple-negative breast cancers: a critical review with an emphasis on the implications for pathologists and oncologists

et al. 2011

Self Cite

View full text Add to dashboard Cite

Breast cancer is a heterogeneous disease encompassing a variety of entities with distinct morphological features and clinical behaviors. Although morphology is often associated with the pattern of molecular aberrations in breast cancers, it is also clear that tumors of the same histological type show remarkably different clinical behavior. This is particularly true for 'basal-like cancer', which is an entity defined using gene expression analysis. The purpose of this article was to review the current state of knowledge of basal-like breast cancers, to discuss the relationship between basal-like and triple-negative breast cancers, and to clarify practical implications of these diagnoses for pathologists and oncologists.

show abstract

Concordance among Gene-Expression–Based Predictors for Breast Cancer

Abstract: Even though different gene sets were used for prognostication in patients with breast cancer, four of the five tested showed significant agreement in the outcome predictions for individual patients and are probably tracking a common set of biologic phenotypes.

Cited by 1,184 publications

References 16 publications

Comparison of gene expression profiles predicting progression in breast cancer patients treated with tamoxifen

Comparison of gene expression profiles predicting progression in breast cancer patients treated with tamoxifen

Short-term outcome of primary operated early breast cancer by hormone and HER-2 receptors

Basal-like and triple-negative breast cancers: a critical review with an emphasis on the implications for pathologists and oncologists

Contact Info

Product

Resources

About